Bedaquiline: A Novel Antitubercular Agent for the Treatment of Multidrug-Resistant Tuberculosis

Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis

(2014) R. C. Hartkoorn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis

(2013) Andreas H. Diacon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis

(2013) Shashank Gupta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

(2013) Elin M. Svensson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Evaluation of Antibiotic Activity Against Mycobacterium abscessus

(2013) Isabelle Lerat et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

(2012) A. H. Diacon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug induced phospholipidosis: An acquired lysosomal storage disorder

(2012) James A. Shayman et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Pharmacokinetics and Pharmacodynamics of TMC207 and ItsN-Desmethyl Metabolite in a Murine Model of Tuberculosis

(2011) Marie-Claude Rouan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism

(2011) Kristin N. Adams et al.   CELL

Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers

(2011) Kelly E. Dooley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Probing the Interaction of the Diarylquinoline TMC207 with Its Target Mycobacterial ATP Synthase

(2011) Anna C. Haagsma et al.   PLoS One

Activities of TMC207, Rifampin, and Pyrazinamide againstMycobacterium tuberculosisInfection in Guinea Pigs

(2010) Shaobin Shang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

TMC207: the first compound of a new class of potent anti-tuberculosis drugs

(2010) Alberto Matteelli et al.   Future Microbiology

Screening for phospholipidosis induced by central nervous drugs: Comparing the predictivity of an in vitro assay to high throughput in silico assays

(2010) Natalie Mesens et al.   TOXICOLOGY IN VITRO

Rates and Mechanisms of Resistance Development in Mycobacterium tuberculosis to a Novel Diarylquinoline ATP Synthase Inhibitor

(2009) E. Huitric et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis

(2009) Andreas H. Diacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis

(2008) R. Rustomjee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis

(2008) Anil Koul et al.   JOURNAL OF BIOLOGICAL CHEMISTRY